ClinicalTrials.gg

Program

IBI3032

A development code. Also written as “IBI3032 tablets”.

Its studies are mostly in Obesity, led by Innovent Biologics.

Furthest: phase 1, since Aug 6, 20254 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics42 open or runningphase 1since Aug 6, 2025Aug 6, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2025First studies: 2 phase 1 studiesFirst studyNCT07120425, NCT07160400
  2. Aug 14, 2025Early phase 1 study in HealthyNCT07134127 · 40 enrolled · China
  3. Sep 7, 2025Phase 1 study in OverweightNCT07170319 · 79 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07170319Overweight · China1Active, not recruitingDec 24, 202579
NCT07160400Obesity · China1CompletedAug 6, 202680
NCT07134127Healthy · ChinaEarly 1CompletedOct 7, 202540
NCT07120425Healthy · United States1RecruitingNov 13, 202532

How it is read

Names in the registry

  • “IBI3032”, 3 entries
  • “IBI3032 tablets”, 1 entry

Codes read as this program: IBI3032.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.